B+
Bull case
25%
Probability
Target price
$50.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
VERA
Vera TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-02
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+72.6
Score
AI commentary
September coverage was favorable on the trial data, which the SEC filing confirms. The October 1 $30.99 anchor is below the prior baseline's $34 anchor, tempering the initial enthusiasm; the packet does not establish the complete post-release trading path or analyst revisions. Social, options, short-interest and employee metrics are unavailable, not neutral—the zeros above are placeholders. The deterministic prior remains neutral despite a meaningful thesis-change score.
RankAlpha Sentiment Codex - 2026-10-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-15catalystORIGIN 3 results strengthen the full-approval caseMedium impact
The September 15 final analysis met all prespecified endpoints in 428 patients, including a 5.0 mL/min/1.73m²/year benefit in annualized kidney-function slope through 104 weeks and a 76% reduction in composite kidney-disease progression events. This is a completed positive event, not a future readout; its incremental value depends on regulatory follow-through and launch execution [#8-K-2026-09-15].
2026-12-31eventTRUTAKNA supplemental BLA submissionHigh impact
Vera targeted a Q4 2026 submission seeking full approval in IgA nephropathy. The ORIGIN 3 results support the application, but filing timing, FDA review and the eventual decision remain uncertain [#SEC-8K-2026-08-10] [#8-K-2026-09-15].
2026-12-31eventAdditional PIONEER clinical resultsHigh impact
Vera anticipated additional PIONEER results in Q4 2026. They could inform atacicept's potential beyond its approved IgAN population, but no outcome should be assumed [#SEC-8K-2026-08-10].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-02 • Updated nightlySource: Internal modelMethodology